TWC
CPRX

TD Waterhouse Canada’s Catalyst Pharmaceutical CPRX Stock Holding History

TD Waterhouse Canada’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.08K Buy
+276
New +$8.15K ﹤0.01% 1907

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
GCM
Gables Capital Management Miami, Florida $277M AUM 41.87% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

TD Waterhouse Canada's CPRX Position: Q2 2026 in Review

TD Waterhouse Canada opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 276 shares worth $7.08K. The stake represents ﹤0.01% of the portfolio and ranks #1907 among its holdings.

178 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • TD Waterhouse Canada held 276 shares of Catalyst Pharmaceutical worth $7.08K as of Q2 2026.
  • Catalyst Pharmaceutical was a new TD Waterhouse Canada position in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1907 holding.
  • 178 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.